DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive ...

Novo Nordisk itself, meanwhile, recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin and calcitonin ... Eli Lilly's dual GIP/GLP-1 tirzepatide to ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

once-weekly injectable GLP-1 and GIP agonist RG6640, and daily injectable GLP-1/GIP agonist RG6641. RG6652 (CT-966) and RG6640 (CT-388) are in phase 1 and phase 2 testing, respectively ...

Mounjaro is the only dual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1 ...

New research suggests that weight loss treatments using GLP-1 and dual GLP-1/GIP receptor agonists can lead to significant fat loss while still maintaining lean muscle mass. The study found that ...

whose drug Zepbound activates the GLP-1 and GIP receptors, currently dominate the obesity drug market. But both products are administered as once-weekly injections. Pfizer is part of a growing ...